195 related articles for article (PubMed ID: 26878157)
1. Strategies in early clinical development for the treatment of basic defects of cystic fibrosis.
Dhooghe B; Haaf JB; Noel S; Leal T
Expert Opin Investig Drugs; 2016; 25(4):423-36. PubMed ID: 26878157
[TBL] [Abstract][Full Text] [Related]
2. Cystic fibrosis transmembrane conductance regulator-modifying medications: the future of cystic fibrosis treatment.
Pettit RS
Ann Pharmacother; 2012; 46(7-8):1065-75. PubMed ID: 22739718
[TBL] [Abstract][Full Text] [Related]
3. F508del-cystic fibrosis transmembrane regulator correctors for treatment of cystic fibrosis: a patent review.
Yang H; Ma T
Expert Opin Ther Pat; 2015; 25(9):991-1002. PubMed ID: 25971311
[TBL] [Abstract][Full Text] [Related]
4. Lumacaftor and ivacaftor in the management of patients with cystic fibrosis: current evidence and future prospects.
Kuk K; Taylor-Cousar JL
Ther Adv Respir Dis; 2015 Dec; 9(6):313-26. PubMed ID: 26416827
[TBL] [Abstract][Full Text] [Related]
5. Cystic fibrosis: insight into CFTR pathophysiology and pharmacotherapy.
Lubamba B; Dhooghe B; Noel S; Leal T
Clin Biochem; 2012 Oct; 45(15):1132-44. PubMed ID: 22698459
[TBL] [Abstract][Full Text] [Related]
6. New pharmacological approaches for cystic fibrosis: promises, progress, pitfalls.
Bell SC; De Boeck K; Amaral MD
Pharmacol Ther; 2015 Jan; 145():19-34. PubMed ID: 24932877
[TBL] [Abstract][Full Text] [Related]
7. CFTR protein repair therapy in cystic fibrosis.
Quintana-Gallego E; Delgado-Pecellín I; Calero Acuña C
Arch Bronconeumol; 2014 Apr; 50(4):146-50. PubMed ID: 24095197
[TBL] [Abstract][Full Text] [Related]
8. Cystic fibrosis transmembrane regulator potentiators as promising cystic fibrosis therapies.
Antoniu SA
Expert Opin Investig Drugs; 2011 Mar; 20(3):423-5. PubMed ID: 21303308
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic options for hydrating airway mucus in cystic fibrosis.
Tildy BE; Rogers DF
Pharmacology; 2015; 95(3-4):117-32. PubMed ID: 25823699
[TBL] [Abstract][Full Text] [Related]
10. Repairing mutated proteins--development of small molecules targeting defects in the cystic fibrosis transmembrane conductance regulator.
Merk D; Schubert-Zsilavecz M
Expert Opin Drug Discov; 2013 Jun; 8(6):691-708. PubMed ID: 23574506
[TBL] [Abstract][Full Text] [Related]
11. Pharmacogenetics of cystic fibrosis treatment.
Carter SC; McKone EF
Pharmacogenomics; 2016 Aug; 17(13):1453-63. PubMed ID: 27490265
[TBL] [Abstract][Full Text] [Related]
12. Repairing the basic defect in cystic fibrosis - one approach is not enough.
Farinha CM; Matos P
FEBS J; 2016 Jan; 283(2):246-64. PubMed ID: 26416076
[TBL] [Abstract][Full Text] [Related]
13. Genetics of cystic fibrosis: CFTR mutation classifications toward genotype-based CF therapies.
Fanen P; Wohlhuter-Haddad A; Hinzpeter A
Int J Biochem Cell Biol; 2014 Jul; 52():94-102. PubMed ID: 24631642
[TBL] [Abstract][Full Text] [Related]
14. New drugs for cystic fibrosis.
Wilschanski M; Kerem E
Expert Opin Investig Drugs; 2011 Sep; 20(9):1285-92. PubMed ID: 21745147
[TBL] [Abstract][Full Text] [Related]
15. Correctors of the basic trafficking defect of the mutant F508del-CFTR that causes cystic fibrosis.
Birault V; Solari R; Hanrahan J; Thomas DY
Curr Opin Chem Biol; 2013 Jun; 17(3):353-60. PubMed ID: 23711435
[TBL] [Abstract][Full Text] [Related]
16. Novel pharmacological strategies to treat cystic fibrosis.
Hanrahan JW; Sampson HM; Thomas DY
Trends Pharmacol Sci; 2013 Feb; 34(2):119-25. PubMed ID: 23380248
[TBL] [Abstract][Full Text] [Related]
17. Searching for a cure for cystic fibrosis. A 25-year quest in a nutshell.
Bosch B; De Boeck K
Eur J Pediatr; 2016 Jan; 175(1):1-8. PubMed ID: 26567541
[TBL] [Abstract][Full Text] [Related]
18. Where are we with transformational therapies for patients with cystic fibrosis?
De Boeck K; Davies JC
Curr Opin Pharmacol; 2017 Jun; 34():70-75. PubMed ID: 28992608
[TBL] [Abstract][Full Text] [Related]
19. Improving complex medical care while awaiting next-generation CFTR potentiators and correctors: The current pipeline of therapeutics.
Goralski JL; Davis SD
Pediatr Pulmonol; 2015 Oct; 50 Suppl 40():S66-73. PubMed ID: 26335956
[TBL] [Abstract][Full Text] [Related]
20. Unmet needs in cystic fibrosis.
Rubin BK
Expert Opin Biol Ther; 2018 Jul; 18(sup1):49-52. PubMed ID: 30063865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
